You need JavaScript to view this

Nerve growth factor affects [sup 11]C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient; Case report

Abstract

Based on animal research suggesting that nerve growth factor (NGF) can stimulate central cholinergic neurons, the known losses of cholinergic innervation of the cortices in Alzheimer's disease (AD), and our experience of infusing NGF to support adrenal grafts in parkinsonian patients, we have initiated clinical trials of NGF infusions into the brain of patients with AD. Here we report a follow-up of our first case, a 69-year-old woman, with symptoms of dementia since 8 years. Intraventricular infusion of 6.6 mg NGF during three months resulted in a marked transient increase in uptake and binding of [sup 11]C-nicotine in frontal and temporal cortex and a persistent increase in cortical blood flow as measured by PET as well as progressive decreases of slow wave EEG activity. After one month of NGF, tests of verbal episodic memory were improved whereas other cognitive tests were not. No adverse effects could be ascribed to the NGF infusion. Taken together, the results of this case study indicate that NGF may counteract cholinergic deficits in AD, and suggest that further clinical trials of NGF infusion in AD are warranted. (authors).
Authors:
Olson, L; [1]  Nordberg, A; [2]  Holst, H von [3] 
  1. Dept. of Histology and Neurobiology, Karolinska Inst., Stockholm (Sweden)
  2. Dept. of Pharmacology, Biomedical Center, Uppsala Univ., Uppsala (Sweden)
  3. Dept. of Neurosurgery, Karolinska Hospital, Stockholm (Sweden); and others
Publication Date:
Jan 01, 1992
Product Type:
Journal Article
Reference Number:
AIX-24-050267; EDB-93-094287
Resource Relation:
Journal Name: Journal of Neural Transmission, Parkinson's Disease and Dementia Section; (Austria); Journal Volume: 4:1
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; NERVOUS SYSTEM DISEASES; GROWTH FACTORS; POSITRON COMPUTED TOMOGRAPHY; BLOOD FLOW; CARBON 11; ELECTROENCEPHALOGRAPHY; NERVE CELLS; NICOTINE; PATIENTS; ALKALOIDS; AMINES; ANIMAL CELLS; AUTONOMIC NERVOUS SYSTEM AGENTS; AZINES; AZOLES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; CARBON ISOTOPES; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVEN-ODD NUCLEI; HETEROCYCLIC COMPOUNDS; ISOTOPES; LIGHT NUCLEI; MINUTES LIVING RADIOISOTOPES; MITOGENS; NUCLEI; ORGANIC COMPOUNDS; ORGANIC NITROGEN COMPOUNDS; PARASYMPATHOLYTICS; PARASYMPATHOMIMETICS; PROTEINS; PYRIDINES; PYRROLES; PYRROLIDINES; RADIOISOTOPES; SOMATIC CELLS; TOMOGRAPHY; 550604* - Medicine- Unsealed Radionuclides in Therapy- (1980-)
OSTI ID:
6239023
Country of Origin:
Austria
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 0936-3076; CODEN: JNPSEJ
Submitting Site:
INIS
Size:
Pages: 79-95
Announcement Date:

Citation Formats

Olson, L, Nordberg, A, and Holst, H von. Nerve growth factor affects [sup 11]C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient; Case report. Austria: N. p., 1992. Web. doi:10.1007/BF02257624.
Olson, L, Nordberg, A, & Holst, H von. Nerve growth factor affects [sup 11]C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient; Case report. Austria. doi:10.1007/BF02257624.
Olson, L, Nordberg, A, and Holst, H von. 1992. "Nerve growth factor affects [sup 11]C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient; Case report." Austria. doi:10.1007/BF02257624. https://www.osti.gov/servlets/purl/10.1007/BF02257624.
@misc{etde_6239023,
title = {Nerve growth factor affects [sup 11]C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient; Case report}
author = {Olson, L, Nordberg, A, and Holst, H von}
abstractNote = {Based on animal research suggesting that nerve growth factor (NGF) can stimulate central cholinergic neurons, the known losses of cholinergic innervation of the cortices in Alzheimer's disease (AD), and our experience of infusing NGF to support adrenal grafts in parkinsonian patients, we have initiated clinical trials of NGF infusions into the brain of patients with AD. Here we report a follow-up of our first case, a 69-year-old woman, with symptoms of dementia since 8 years. Intraventricular infusion of 6.6 mg NGF during three months resulted in a marked transient increase in uptake and binding of [sup 11]C-nicotine in frontal and temporal cortex and a persistent increase in cortical blood flow as measured by PET as well as progressive decreases of slow wave EEG activity. After one month of NGF, tests of verbal episodic memory were improved whereas other cognitive tests were not. No adverse effects could be ascribed to the NGF infusion. Taken together, the results of this case study indicate that NGF may counteract cholinergic deficits in AD, and suggest that further clinical trials of NGF infusion in AD are warranted. (authors).}
doi = {10.1007/BF02257624}
journal = {Journal of Neural Transmission, Parkinson's Disease and Dementia Section; (Austria)}
volume = {4:1}
journal type = {AC}
place = {Austria}
year = {1992}
month = {Jan}
}